IRVINE, Calif., Nov. 07, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at four investor conferences in November 2016. The first conference is the Stephens 2016 Fall Investment Conference in New York, NY.
| Event: | Stephens 2016 Fall Investment Conference | ||
| Date: | Wednesday, November 9, 2016 | ||
| Time: | 11:00 am ET / 8:00 am PT | ||
| Participant: | Vaseem Mahboob, Chief Financial Officer | ||
The second conference is the Stifel 2016 Healthcare Conference in New York, NY.
| Event: | Stifel 2016 Healthcare Conference | ||
| Date: | Tuesday, November 15, 2016 | ||
| Time: | 11:00 am ET / 8:00 am PT | ||
| Participant: | John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer | ||
The third conference is the Canaccord Genuity Medical Technologies and Diagnostics Forum in New York, NY.
| Event: | Canaccord Genuity Medical Technologies and Diagnostics Forum | ||
| Date: | Thursday, November 17, 2016 | ||
| Time: | 8:30 am ET / 5:30 am PT | ||
| Participant: | John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer | ||
The fourth conference is the 28th Annual Piper Jaffray Healthcare Conference in New York, NY.
| Event: | 28th Annual Piper Jaffray Healthcare Conference | ||
| Date: | Wednesday, November 30, 2016 | ||
| Time: | 9:30 am ET / 6:30 am PT | ||
| Participant: | Vaseem Mahboob, Chief Financial Officer | ||
An audio webcast of the Company’s presentations will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentations will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020


Washington Post Publisher Will Lewis Steps Down After Layoffs
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



